“Preclinical formulation for the pharmacokinetics and efficacy of GBO-006, a selective polo like kinase 2 (PLK2) inhibitor for the treatment of triple negative breast cancer” (2016) ADMET and DMPK, 4(4), pp. 314–326. doi:10.5599/admet.4.4.341.